130 related articles for article (PubMed ID: 25297456)
1. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
[TBL] [Abstract][Full Text] [Related]
2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
3. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
4. Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.
Suri A; Pusalkar S; Li Y; Prakash S
Clin Pharmacol Drug Dev; 2016 May; 5(3):180-7. PubMed ID: 27163496
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.
Kumar A; S VK; Gurav S; Zainuddin M; Dewang P; Kethiri RR; Rajagopal S; Mullangi R
Biomed Chromatogr; 2013 Dec; 27(12):1590-4. PubMed ID: 23788266
[TBL] [Abstract][Full Text] [Related]
6. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.
Suri A; Pham T; MacLean DB
Clin Pharmacol Drug Dev; 2016 May; 5(3):188-95. PubMed ID: 27163497
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals.
Goto A; Moriya Y; Takeuchi T; Mandai T; Tagawa Y; Kondo T; Asahi S
Drug Res (Stuttg); 2016 Apr; 66(4):217-22. PubMed ID: 26418412
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
10. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
12. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
13. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
15. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
17. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
18. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
Roviello G; Pacifico C; Chiriacò G; Generali D
Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
20. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]